213O - Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session New approaches in rare thoracic tumors
Topics Mesothelioma
Thoracic Malignancies
Presenter Nick Pavlakis
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors N. Pavlakis1, F. Grosso2, N. Steele3, A. Nowak4, S. Novello5, S. Popat6, L. Greillier7, M. Reck8, T. Kitzing9, G. Scagliotti5
  • 1Northern Cancer Institute, 2065 - St Leonards/AU
  • 2Department Of Oncology, SS Antonio e Biagio Hospital, Alessandria/IT
  • 3The Beatson West of Scotland Cancer Centre, Glasgow/GB
  • 4School Of Medicine, Faculty Of Medicine And Health Sciences, University of Western Australia, Crawley/AU
  • 5Department Of Oncology, S. Luigi Hospital, University of Turin, Torino/IT
  • 6Royal Marsden Hospital NHS Foundation Trust, London/GB
  • 7Assistance Publique - Hôpitaux de Marseille, Aix Marseille University, Marseille/FR
  • 8Department Of Thoracic Oncology, Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Grosshansdorf/DE
  • 9Boehringer Ingelheim Pharma GmbH & Co KG, Biberach/DE


The randomised Phase II/III LUME-Meso study is evaluating nintedanib + pemetrexed/cisplatin versus placebo + pemetrexed/cisplatin (≤6 cycles), followed by nintedanib or placebo maintenance, in chemo-naïve MPM. In the Phase II part, nintedanib treatment led to improved progression-free survival (PFS; hazard ratio [HR] = 0.54; p = 0.010) and a trend for longer overall survival (OS; HR = 0.77; p = 0.319) compared with placebo. Patients with epithelioid tumours derived greatest benefit. Plasma angiogenic factors and genomic markers were explored for potential associations with treatment outcome in the Phase II epithelioid population.